Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Connect Biopharma Holdings Ltd

Get SEC filing alerts via email and in your feed for Connect Biopharma Holdings Ltd

CNTB

Connect Biopharma Holdings Ltd

About Connect Biopharma Holdings Ltd

Connect Biopharma is a clinical-stage biopharmaceutical company developing monoclonal antibodies targeting respiratory diseases like asthma and COPD. Its lead product, rademikibart, inhibits IL-4Rα to treat eosinophilic inflammation, aiming to improve acute and chronic care. The company focuses on innovative therapies, clinical trials, and strategic collaborations, with a pipeline addressing significant unmet medical needs in respiratory and inflammatory conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Connect Biopharma Holdings Ltd

1
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports $19.4 Million Net Loss in Q1 2026, Revenue Increases to $169,000

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports Increased Net Loss and Advances Rademikibart Trials

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports Revenue Decline and Increased Net Losses for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports $12.9 Million Net Loss in Q2 2025 Amid Increased R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports $10.3 Million Net Loss for Q1 2025, Advances Clinical Programs

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Connect Biopharma Holdings Ltd Connect Biopharma Reports $15.6 Million Net Loss for 2024, Revenue Increases to $26 Million

Via official filing (AI summary) | about 1 year ago | 0 comments